Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00660088 · ClinicalTrials.gov registry record

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

A clinical trial of Alzheimers Disease, sponsored by Cerecin.

Completed
Registry status
60
Enrollment target
1
Study location

NCT00660088: Completed study of Alzheimers Disease, sponsored by Cerecin.

NCT00660088 is a study of Alzheimers Disease that has completed, run by Cerecin. The registered enrollment target is 60 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00660088, a study of Alzheimers Disease, has completed, sponsored by Cerecin.

COMPLETED
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

AC-1202 (Ketasyn) is a nutritional beverage currently being studied in neurodegenerative conditions including Alzheimer's disease. The current study is a randomized, open-label trial to compare the safety, tolerability, and PK profiles of 3 formulations of Ketasyn administered on a daily basis for 14 days, with and without a 7-day titration period, in normal, healthy elderly volunteers.

Conditions Studied

Alzheimers Disease

Interventions

  • OTHER Ketasyn

Study Locations (1)

Florida

  • Meridien Research Center - St. Petersburg

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2008-04
Est. Completion 2008-08

Sponsor

Cerecin

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00660088

The ClinicalTrials.gov registry entry for NCT00660088 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The listed sponsor is Cerecin, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which Ketasyn is the first listed.

NCT00660088 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00660088 about?

NCT00660088 is a clinical study titled "Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly". AC-1202 (Ketasyn) is a nutritional beverage currently being studied in neurodegenerative conditions including Alzheimer's disease. The current study is a randomized, open-label trial to compare the safety, tolerability, and PK profiles of 3 formulations of Ketasyn administered on a daily basis for 1...

What is the current status of trial NCT00660088?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2008-04. Estimated completion is 2008-08.

What conditions does trial NCT00660088 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT00660088?

The interventions under investigation include: Ketasyn (OTHER).

Who is sponsoring clinical trial NCT00660088?

This trial is sponsored by Cerecin, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00660088 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.